Clinical trials
catalyst calendar across sponsors →Studies where EDIT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional · 2 observational
Held by 12 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, MARSHALL WACE, LLP, D. E. Shaw & Co., Inc., AQR CAPITAL MANAGEMENT LLC, TWO SIGMA INVESTMENTS, LP, +7 more) · FINRA short interest 18.2 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 3 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301NCT06363760observationalAdverse events of special interest (AESI) | — | Enrolling by invitation | Other: Safety and efficacy assessments | Sickle Cell Disease, Transfusion-dependent Beta-Thalassemia, Hemoglobinopathies | 54 | Aug 2040 | ≤ 5,126 d | 2025-04-02 |
| EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)NCT05444894Proportion of participants achieving engraftment defined as neutrophil engraftment (defined as demonstrating absolute neutrophil count (ANC) ≥ 0.5 x 10^9/L post EDIT-301 infusion for 3 consecutive measurements obtained on different days)Open-label · Treatment | Phase 1/2 | Active, not recruiting | Genetic: EDIT-301 | Transfusion Dependent Beta Thalassemia, Hemoglobinopathies, Thalassemia Major, Thalassemia Intermedia | 9 | Sep 2025 | — | 2025-04-02 |
| A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)NCT04853576Proportion of subjects achieving complete resolution of severe vaso-occlusive events (VOEs)Open-label · Treatment | Phase 1/2 | Active, not recruiting | Genetic: EDIT-301 | Sickle Cell Disease, Hemoglobinopathies | 45 | Aug 2025 | — | 2025-01-31 |
| Single Ascending Dose Study in Participants With LCA10NCT03872479Frequency of Adverse Events related to EDIT-101Non-randomized · Open-label · Treatment | Phase 1/2 | Unknown status | Drug: EDIT-101 | Leber Congenital Amaurosis 10, Inherited Retinal Dystrophies, Eye Diseases, Hereditary, Retinal Disease, Retinal Degeneration, Vision Disorders, Eye Disorders Congenital | 34 | 2025-05-23 | — | 2022-12-05 |
| Natural History Study of CEP290-Related Retinal DegenerationNCT03396042observationalCharacterize CEP290-related retinal degeneration | — | Completed | — | Blindness, Leber Congenital Amaurosis 10, Vision Disorders, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Retinal Disease, Retinal Degeneration | 26 | 2022-05-06actual | — | 2022-05-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19